Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D5SZK9
|
|||
| Drug Name |
HMI-102
|
|||
| Drug Type |
Gene therapy
|
|||
| Indication | Phenylketonuria [ICD-11: 5C50.0; ICD-10: E70, E70.1] | Phase 1/2 | [1] | |
| Company |
Homology Medicines
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Phenylalanine hydroxylase (PAH) | Target Info | . | [2] |
| BioCyc | Phenylalanine degradation/tyrosine biosynthesis | |||
| KEGG Pathway | Phenylalanine metabolism | |||
| Phenylalanine, tyrosine and tryptophan biosynthesis | ||||
| Metabolic pathways | ||||
| Biosynthesis of amino acids | ||||
| Pathwhiz Pathway | Phenylalanine and Tyrosine Metabolism | |||
| WikiPathways | SIDS Susceptibility Pathways | |||
| Biogenic Amine Synthesis | ||||
| Metabolism of amino acids and derivatives | ||||
| Abnormal metabolism in phenylketonuria | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03952156) A Phase 1/2 Open-Label, Randomized, Concurrently-Controlled, Dose Escalation Study to Evaluate the Safety and Efficacy of HMI-102 in Adult PKU Subjects With PAH Deficiency. U.S.National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Homology Medicines | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.